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QOL Metric O-GVHD Estimate P NIH Eye score Estimate P
FACT-G No 0* 0.006 0 0* 0.05
ˇ
Yes -2.1 1 -0.7 0.40
Abstracts / Biol Blood Marrow Transplant 20 (2014) S257eS285 S269may be independent of whether the phenotype of the donor
immune cells is malignant and that GvHD and GvL may be
more a quantitative than qualitative effect.2 or 3 -2.5 0.01
FACT-TOI No 0* <0.001 0 0* 0.03
ˇ
Yes -2.6 1 -1.5 0.04
2 or 3 -2.4 0.01
FACT-BMT No 0* 0.002 0 0* 0.08
ˇ
Yes -3.0 1 -1.3 0.19
2 or 3 -3 0.03
Lee Score** No 0* <0.001 0 0* 0.01
ˇ
Yes 2.8 1 1.7 0.01
2 or 3 2.1 0.02
ˇ
overall P value; *Estimate 0-reference category; **Lee symptom score-eye
component excluded418
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Background: Ocular GVHD (o-GVHD) is a known manifes-
tation of chronic GVHD (cGVHD). There are no prospective
studies of factors associated with o-GVHD or its impact on
quality of life (QOL). We analyzed the above endpoints using
the cGVHD consortium database; a prospective multi-center
longitudinal observational study.
Methods: The study included patients with cGVHD requiring
systemic treatment and enrolled within 3 months of diag-
nosis. O-GVHD was deﬁned as NIH eye score > 0 and patient
reported symptoms (> 1 on 0-10 eye related symptoms or
>20 on Lee symptom eye score). Variables associated with o-
GVHD at enrollment and subsequent new onset o-GVHD, and
the associations with QOL were studied.
Results: The cumulative incidence of o-GVHD at 2 y after
cGVHD diagnosis was 58%. Of the 290 patients with o-GVHD,
117 (40%) had it within 3 months of cGVHD diagnosis (“early
o-GVHD”). Chronic GVHD characteristics associated with
early o-GVHD included: more severe global cGVHD
(P<0.001), and greater severity of mouth (P¼0.001), esoph-
agus (P¼0.002), and liver (P<0.001) involvement. In a
multivariable analysis, female sex (OR 2.0, P¼0.01) and
higher prednisone dose at enrollment (P¼0.04) were asso-
ciated with o-GVHD. Early o-GVHD was not associated with
subsequent non-relapse mortality (HR 1.2, P¼0.53) or sur-
vival (HR 1.1, P¼0.85).
Late o-GVHD (new onset > 3 months after cGVHD diag-
nosis) occurred in 68 patients. The cumulative incidence of
late o-GVHD at 2-y post enrollment was 39%. Inmultivariable
modeling, presence of prior grade I-IV aGVHD (HR 1.8,
P¼0.03) was associated with shorter time to late o-GVHD,
while female donor into male recipient (HR 0.5, P¼0.05) was
associated with longer time to late o-GVHD onset.
The Table shows the association of o-GVHD with QOL
metrics, using all available visit data adjusted for center
effect, months since enrollment, platelet count, NIH
severity, bilirubin, prior aGVHD, and overlap vs. classic
cGVHD.
Conclusion: This large multicenter, prospective study shows
that o-GVHD affects 58% of patients at 2 y after a diagnosis of
cGVHD and is statistically associated with worse QOL and
more cGVHD symptoms compared to patients with cGVHD
without ocular involvement. Since o-GVHD may be due to
permanent destruction of lacrimal glands, prophylactic or
pre-emptive clinical trial strategies prior to onset ofirreversible dry eye syndrome are needed. Women, patients
on higher doses of prednisone, and those with a history of
acute GVHD seem to be at higher risk for o-GVHD.419
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Graft vs. host (GVH) effect mediated by donor T cells are
responsible for a signiﬁcant measure of therapeutic beneﬁt
as well as toxicity observed following stem cell trans-
plantation (SCT) between HLA-identical donors and re-
cipients. Donor T cell-mediated GVH effects may be
inﬂuenced by the aggregate alloreactivity to minor histo-
compatibility antigens (mHA) presented by the HLA in each
donor-recipient pair (DRP). The cumulative mHA variation in
each DRPmay thus be regarded as the alloreactivity potential
(AP) of that pair. To estimate AP in DRP, whole exome
sequencing (WES) of 4 matched-related (MRD) and 5 unre-
lated (URD) pairs was performed and revealed extensive
coding variation between them. To quantify the contribution
of exome sequence variation to AP, data from each DRP was
ﬁltered to isolate non-synonymous single nucleotide poly-
morphisms (SNP) in the GVH direction (polymorphisms
present in recipient and absent in donor). Logically, the SNP
involved in encoding peptides presented on the HLA in each
DRP will contribute to the AP in that pair. To identify these
peptides, the nucleotide sequence ﬂanking all of the several
thousand SNP in each DRP was obtained with the ANNOVAR
software package. All possible resulting nonameric-peptides
were interrogated in-silico for their likelihood to be pre-
sented by each of the 6 HLA class I molecules in individual
DRP, using the Immune-Epitope Database (IEDB) SMM al-
gorithm. The IEDB-SMM algorithm predicted between
1,043,514 and 366,426 peptides/DRP (w 18 peptides/SNP).
Peptide-HLA binding afﬁnity estimate was reported as an
IC50 value, which when <500 nM, predicts that peptides
